Literature DB >> 30274277

Topical Delivery of Senicapoc Nanoliposomal Formulation for Ocular Surface Treatments.

Jie Liang Phua1, Aihua Hou2,3, Yuan Siang Lui4, Tanima Bose5, George Kanianthara Chandy6, Louis Tong7,8,9,10, Subbu Venkatraman11, Yingying Huang12.   

Abstract

Topical ophthalmologic treatments have been facing great challenges with main limitations of low drug bioavailability, due to highly integrative defense mechanisms of the eye. This study rationally devised strategies to increase drug bioavailability by increasing ocular surface residence time of drug-loaded nanoliposomes dispersed within thermo-sensitive hydrogels (Pluronic F-127). Alternatively, we utilized sub-conjunctival injections as a depot technique to localize nanoliposomes. Senicapoc was encapsulated and sustainably released from free nanoliposomes and hydrogels formulations in vitro. Residence time increased up to 12-fold (60 min) with 24% hydrogel formulations, as compared to 5 min for free liposomes, which was observed in the eyes of Sprague-Dawley rats using fluorescence measurements. Pharmacokinetic results obtained from flushed tears, also showed that the hydrogels had greater drug retention capabilities to that of topical viscous solutions for up to 60 min. Senicapoc also remained quantifiable within sub-conjunctival tissues for up to 24 h post-injection.

Entities:  

Keywords:  hydrogel; liposomes; ocular; senicapoc

Mesh:

Substances:

Year:  2018        PMID: 30274277      PMCID: PMC6213297          DOI: 10.3390/ijms19102977

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  44 in total

Review 1.  Drug delivery for posterior segment eye disease.

Authors:  D H Geroski; H F Edelhauser
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-04       Impact factor: 4.799

2.  Therapeutic potential of KCa3.1 blockers: recent advances and promising trends.

Authors:  Heike Wulff; Neil A Castle
Journal:  Expert Rev Clin Pharmacol       Date:  2010-05       Impact factor: 5.045

3.  Application of liposome encapsulation technique to improve anti-carcinoma effect of resveratrol.

Authors:  Xin-Yi Lu; Song Hu; Yi Jin; Li-Yan Qiu
Journal:  Drug Dev Ind Pharm       Date:  2011-08-19       Impact factor: 3.225

Review 4.  Review of ocular drug delivery.

Authors:  Yasmin Sultana; R Jain; M Aqil; Asgar Ali
Journal:  Curr Drug Deliv       Date:  2006-04       Impact factor: 2.565

5.  Blockade of the intermediate-conductance Ca(2+)-activated K+ channel inhibits the angiogenesis induced by epidermal growth factor in the treatment of corneal alkali burn.

Authors:  Huike Yang; Xiaodong Li; Jing Ma; Xiaohong Lv; Shu Zhao; Wen Lang; Yafang Zhang
Journal:  Exp Eye Res       Date:  2013-03-07       Impact factor: 3.467

6.  Ocular delivery of pRNA nanoparticles: distribution and clearance after subconjunctival injection.

Authors:  Liang Feng; S Kevin Li; Hongshan Liu; Chia-Yang Liu; Kathleen LaSance; Farzin Haque; Dan Shu; Peixuan Guo
Journal:  Pharm Res       Date:  2013-12-03       Impact factor: 4.200

7.  Poly(N-isopropylacrylamide)-chitosan as thermosensitive in situ gel-forming system for ocular drug delivery.

Authors:  Yanxia Cao; Can Zhang; Wenbin Shen; Zhihong Cheng; Liangli Lucy Yu; Qineng Ping
Journal:  J Control Release       Date:  2007-05-17       Impact factor: 9.776

8.  Sustained release of an anti-glaucoma drug: demonstration of efficacy of a liposomal formulation in the rabbit eye.

Authors:  Jayaganesh V Natarajan; Sujay Chattopadhyay; Marcus Ang; Anastasia Darwitan; Selin Foo; Ma Zhen; Magdalene Koo; Tina T Wong; Subbu S Venkatraman
Journal:  PLoS One       Date:  2011-09-09       Impact factor: 3.240

9.  Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye.

Authors:  Jayaganesh V Natarajan; Marcus Ang; Anastasia Darwitan; Sujay Chattopadhyay; Tina T Wong; Subbu S Venkatraman
Journal:  Int J Nanomedicine       Date:  2012-01-05

10.  KCa3.1 ion channel: A novel therapeutic target for corneal fibrosis.

Authors:  Govindaraj Anumanthan; Suneel Gupta; Michael K Fink; Nathan P Hesemann; Douglas K Bowles; Lindsey M McDaniel; Maaz Muhammad; Rajiv R Mohan
Journal:  PLoS One       Date:  2018-03-19       Impact factor: 3.240

View more
  3 in total

1.  HDL nanoparticles have wound healing and anti-inflammatory properties and can topically deliver miRNAs.

Authors:  Junyi Wang; Andrea E Calvert; Nihal Kaplan; Kaylin M McMahon; Wending Yang; Kurt Q Lu; Han Peng; C Shad Thaxton; Robert M Lavker
Journal:  Adv Ther (Weinh)       Date:  2020-09-30

Review 2.  Drug Delivery Challenges and Current Progress in Nanocarrier-Based Ocular Therapeutic System.

Authors:  Md Habban Akhter; Irfan Ahmad; Mohammad Y Alshahrani; Alhanouf I Al-Harbi; Habibullah Khalilullah; Obaid Afzal; Abdulmalik S A Altamimi; Shehla Nasar Mir Najib Ullah; Abhijeet Ojha; Shahid Karim
Journal:  Gels       Date:  2022-01-28

Review 3.  Nanocarriers for ocular drug delivery: current status and translational opportunity.

Authors:  Srividya Gorantla; Vamshi Krishna Rapalli; Tejashree Waghule; Prem Prakash Singh; Sunil Kumar Dubey; Ranendra N Saha; Gautam Singhvi
Journal:  RSC Adv       Date:  2020-07-24       Impact factor: 4.036

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.